Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31019193 | 1.00 | NR1H4 (0.62) | NR1H4EPHX2HDAC1NAMPTL3MBTL1 | |
| SCHEMBL14979282 | 0.90 | NR1H4 (0.50) | NR1H4EPHX2HDAC1NAMPTL3MBTL1 | |
| SCHEMBL30901987 | 0.90 | NR1H4 (0.50) | NR1H4EPHX2HDAC1NAMPTL3MBTL1 | |
| SCHEMBL1205128 | 0.89 | NR1H4 (0.48) | NR1H4EPHX2HDAC1NAMPTL3MBTL1 | |
| SCHEMBL30910306 | 0.89 | NR1H4 (0.48) | NR1H4EPHX2HDAC1NAMPTL3MBTL1 | |
| SCHEMBL30964980 | 0.88 | NR1H4 (0.48) | NR1H4HDAC1NAMPTL3MBTL1GAA | |
| SCHEMBL1244785 | 0.86 | NR1H4 (0.61) | NR1H4EPHX2HDAC1NAMPTL3MBTL1 | |
| SCHEMBL25256049 | 0.85 | NR1H4 (0.45) | NR1H4EPHX2HDAC1NAMPTL3MBTL1 | |
| SCHEMBL1018437 | 0.85 | NR1H4 (0.62) | NR1H4EPHX2HDAC1NAMPTL3MBTL1 | |
| SCHEMBL3657504 | 0.85 | NR1H4 (0.45) | NR1H4EPHX2HDAC1NAMPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0976722-B1 | BENZAMIDINE DERIVATIVES | AJINOMOTO KK (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-7396844-B1 | Benzamidine derivatives | AJINOMOTO CO., INC. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-20050026929-A1 | Novel phenyl derivatives as inducers of apoptosis | AXYS PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | US | disclosed |
| WO-2003090680-A2 | NOVEL PHENYL DERIVATIVES AS INDUCERS OF APOPTOSIS | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| EP-0976722-A1 | BENZAMIDINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026929-A1 | Novel phenyl derivatives as inducers of apoptosis | BAX, BAD, CASP3 | NR1H4 432/4885EPHX2 3120/4885HDAC1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.